$16.83 Million in Sales Expected for Teligent (TLGT) This Quarter

Wall Street brokerages forecast that Teligent (NASDAQ:TLGT) will post $16.83 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Teligent’s earnings. The lowest sales estimate is $16.50 million and the highest is $17.15 million. Teligent posted sales of $18.41 million during the same quarter last year, which suggests a negative year over year growth rate of 8.6%. The firm is scheduled to issue its next earnings results on Tuesday, August 14th.

According to Zacks, analysts expect that Teligent will report full-year sales of $73.69 million for the current year, with estimates ranging from $72.50 million to $74.51 million. For the next financial year, analysts anticipate that the firm will report sales of $101.60 million per share, with estimates ranging from $96.70 million to $106.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Teligent.

Teligent (NASDAQ:TLGT) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01). Teligent had a negative return on equity of 27.25% and a negative net margin of 28.98%. The company had revenue of $14.55 million for the quarter, compared to the consensus estimate of $15.62 million.

A number of research firms have commented on TLGT. Zacks Investment Research cut shares of Teligent from a “hold” rating to a “sell” rating in a research report on Thursday, May 10th. Canaccord Genuity set a $4.00 price objective on shares of Teligent and gave the stock a “hold” rating in a research report on Wednesday, May 9th. Finally, ValuEngine raised shares of Teligent from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $7.00.

Teligent traded down $0.02, reaching $2.73, during midday trading on Tuesday, MarketBeat reports. 2,200 shares of the company were exchanged, compared to its average volume of 711,966. The company has a debt-to-equity ratio of 3.07, a current ratio of 2.73 and a quick ratio of 1.69. Teligent has a one year low of $2.43 and a one year high of $9.54. The stock has a market cap of $148.77 million, a price-to-earnings ratio of -14.42 and a beta of 0.73.

Several institutional investors have recently made changes to their positions in TLGT. Prosight Management LP bought a new stake in shares of Teligent in the first quarter valued at about $8,308,000. Elk Creek Partners LLC boosted its position in shares of Teligent by 81.3% in the first quarter. Elk Creek Partners LLC now owns 3,554,958 shares of the company’s stock valued at $11,945,000 after acquiring an additional 1,594,514 shares during the period. Broadfin Capital LLC boosted its position in shares of Teligent by 35.1% in the fourth quarter. Broadfin Capital LLC now owns 1,925,415 shares of the company’s stock valued at $6,989,000 after acquiring an additional 500,000 shares during the period. Algert Global LLC bought a new stake in shares of Teligent in the first quarter valued at about $1,056,000. Finally, venBio Select Advisor LLC boosted its position in shares of Teligent by 5.0% in the first quarter. venBio Select Advisor LLC now owns 5,299,431 shares of the company’s stock valued at $17,806,000 after acquiring an additional 250,000 shares during the period. 62.11% of the stock is owned by institutional investors.

Teligent Company Profile

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Get a free copy of the Zacks research report on Teligent (TLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply